Managed Healthcare Executive April 30, 2024
MHE Staff

In a discussion with Managed Healthcare Executive, Cate Lockhart, Pharm.D., Ph.D., executive director, Biologics and Biosimilars Collective Intelligence Consortium, talks about whether or not she favors ending interchangeability designation for biosimilars.

Lockhart spoke about biosimilars at an Asembia 2024 session yesterday but was interviewed earlier this month...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Conferences / Podcast, Pharma / Biotech, Trends
STAT+: NVIDIA’s Kimberly Powell touts progress on AI in drug discovery
Big pharma ignores low-cost migraine solution
Sanders: Weight loss drug could bankrupt healthcare system
J&J Joins Chase for Hot Immunology Target With $850M Proteologix Acquisition
Going beyond A, B & O: Thermo Fisher unveils DNA test for the rarest blood types

Share This Article